Stockscreener 앱 받기
4.28
3.63%
0.15
시간 외 거래:
4.31
0.03
+0.70%
Curevac N V 주식(CVAC)의 최신 뉴스
BioNTech Completes CureVac Acquisition to Bolster mRNA Leadership - TipRanks
Will CureVac N.V. stock rally after Fed decisionsTrade Risk Report & Proven Capital Preservation Tips - Улправда
BioNTech : Publishes Final Results of the Exchange Offer for CureVac - marketscreener.com
Will CureVac N.V. stock remain a Wall Street favoriteInflation Watch & Risk Controlled Stock Alerts - Улправда
BioNTech Closes CureVac Acquisition - marketscreener.com
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field - The Manila Times
Biontech closes acquisition of CureVac - marketscreener.com
BioNTech Completes Acquisition of CureVac with 86.75% Share Tendered - Quiver Quantitative
Two early mRNA firms join forces as BioNTech buys CureVac - Stock Titan
CureVac N.V.(NasdaqGM: CVAC) dropped from S&P Global BMI Index - marketscreener.com
CureVac (NASDAQ:CVAC) Trading Down 9.9%Time to Sell? - MarketBeat
CureVac N.V. (NASDAQ:CVAC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
CureVac N.V. (NASDAQ:CVAC) Nasdaq Composite Tracks Biotech Momentum - Kalkine Media
BioNTech Shares Gain Momentum from Acquisition and Clinical Progress - AD HOC NEWS
CureVac Enters Oversold Territory (CVAC) - Nasdaq
CureVac Shareholders Approve BioNTech Exchange Offer - MSN
BioNTech's Oncology Pipeline Gains Momentum with Key Clinical Data () - aktiencheck.de
Trading Recap: Chien thuat ca cuoc dai han de kiem tienQuarterly Earnings Summary & Daily Growth Stock Tips - BỘ NỘI VỤ
CureVac Acquisition Finalized as BioNTech Secures Controlling Stake () - aktiencheck.de
CureVac Valuation After 2025 Rebound and DCF Suggests Large Gap to Fair Value - Yahoo Finance
Can CureVac N.V. stock reach $100 price targetWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
CureVac N.V. (CVAC): A Bull Case Theory - Finviz
Can CureVac N.V. stock sustain market leadershipGlobal Markets & Proven Capital Preservation Tips - Newser
Reassessing CureVac (NasdaqGM:CVAC) Valuation After Its Removal From the NASDAQ Biotechnology Index - Sahm
BioNTech Satisfies Minimum Condition in CureVac Exchange Offer - TipRanks
BioNTech satisfies minimum condition in CureVac exchange offer - MSN
Biontech achieves minimum condition in CureVac exchange offer - marketscreener.com
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - The Manila Times
BioNTech Announces Successful Tender of Over 81% of CureVac Shares, Subsequent Offering Period Now Open - Quiver Quantitative
BioNTech Achieves Minimum Condition in CureVac Exchange Offer - Benzinga
Movement Recap: Can MFSG stock resist broad market declinesQuarterly Performance Summary & Free Low Drawdown Momentum Trade Ideas - BỘ NỘI VỤ
A Pivotal Deadline for CureVac Shareholders () - aktiencheck.de
Can New Board Leadership at CureVac (CVAC) Shift the Narrative After Recent Earnings Decline? - simplywall.st
CureVac NV Faces Valuation Shift Amid Declining Financial Performance Indicators - Markets Mojo
How CureVac N.V. stock reacts to Fed rate cutsEarnings Risk Report & Reliable Volume Spike Trade Alerts - moha.gov.vn
Carlson Capital L.P. Makes New Investment in CureVac N.V. $CVAC - MarketBeat
Transcript : CureVac N.V.Shareholder/Analyst Call - MarketScreener
CureVac (NASDAQ:CVAC) Sees Large Volume IncreaseHere's What Happened - MarketBeat
BioNTech Advances with CureVac Exchange Offer Approval - TipRanks
[6-K] BioNTech SE Current Report (Foreign Issuer) | BNTX SEC FilingForm 6-K - Stock Titan
CureVac Reports Q3 2025 Financial Results and Updates - MSN
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com Nigeria
CureVac Form 6-K files EGM voting outcomes, joins BioNTech F-4 - Stock Titan
BioNTech (BNTX) Moves Forward with CureVac Acquisition - GuruFocus
BioNTech’s exchange offer for German mRNA vaccine peer CureVac set to expire Dec. 3 - Seeking Alpha
BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration - The Manila Times
BioNTech Completes CureVac Share Exchange Offer Following Shareholder Approval - Quiver Quantitative
BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025 - TradingView — Track All Markets
BioNTech exchange offer for CureVac expires December 3 - StreetInsider
CureVac NV earnings beat by €0.08, revenue topped estimates - Investing.com South Africa
CureVac NV (FRA:5CV) PS Ratio : 14.01 (As of Nov. 25, 2025) - GuruFocus
EQS-News: CureVac Announces Voting Results of Extraordinary General Meeting - sharewise.com
CureVac (Nasdaq: CVAC) shareholders approve BioNTech exchange offer with 99.16% vote - Stock Titan
CureVac Announces Voting Results of Extraordinary General Meeting - The Derrick
How Investors May Respond To CureVac (CVAC) Reporting Sharp Decline in Quarterly Sales - Yahoo Finance
0.31%
0.33%
자본화:
|
볼륨(24시간):